Price$1.80-0.04 (-2.44%)
2026-03-052026-06-08
News · 26 weeks69-26%
2025-12-142026-06-07
Mix5290d
- SEC Filings25(48%)
- Other17(33%)
- Offering3(6%)
- Earnings3(6%)
- Insider3(6%)
- Leadership1(2%)
Latest news
25 items- SECSEC Form DFRN14A filed by Seer Inc.DFRN14A - Seer, Inc. (0001726445) (Subject)
- PRSeer Files Definitive Proxy Materials and Mails Letter to StockholdersReinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of
- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSEC Form DEFC14A filed by Seer Inc.DEFC14A - Seer, Inc. (0001726445) (Subject)
- SECSEC Form DEFC14A filed by Seer Inc.DEFC14A - Seer, Inc. (0001726445) (Subject)
- PRSeer Files ITC Complaint Against NanomicsREDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a complaint at the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd. The Brigham and Women's Hospital has joined the ITC complaint as well. The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC
- SECSEC Form DFAN14A filed by Seer Inc.DFAN14A - Seer, Inc. (0001726445) (Subject)
- PRThe Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All StockholdersCorrects the Board's Flawed Reasons for Rejecting its Credible, Premium Acquisition Offer in Apparent Breach of its Fiduciary Duty Reaffirms its Fully Financed Proposal to Acquire Seer for $2.40 per Share in Cash – a 42% Premium to the Unaffected Share Price – and a CVR for Stockholders to Receive 80% of the Net Proceeds from the Company's Assets Files Preliminary Proxy Statement to Give Stockholders the Opportunity to Elect Three New Qualified, Independent Directors Who Intend to Advocate for a Strategic Review Process Aimed at Maximizing Value for All Seer Stockholders Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), wh
- PRSeer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026REDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference, taking place May 31 to June 4 at the San Diego Convention Center. At the meeting, Seer and a broad set of collaborators will demonstrate how the Proteograph® Product Suite is enabling deep, unbiased, scalable proteomics with peptide-level precision, empowering researchers to uncover hidden biological insights and drive new discovery across translational and population-scale research. Seer's presence at ASMS 2026 will span a featur
- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSEC Form DEFA14A filed by Seer Inc.DEFA14A - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- INSIDERPRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)4 - Seer, Inc. (0001726445) (Issuer)
- PRSeer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC GroupREDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the "Board") has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), to acquire all of the outstanding shares of Seer's Class A common stock for $2.40 per share in cash plus a contingent value right (the "May 14 Revised Proposal"). Consistent with its fiduciary duties, the Board carefully reviewed the May 14 Revised
- SECSEC Form PREC14A filed by Seer Inc.PREC14A - Seer, Inc. (0001726445) (Subject)
- SECSEC Form PREC14A filed by Seer Inc.PREC14A - Seer, Inc. (0001726445) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)
- SECSEC Form DFAN14A filed by Seer Inc.DFAN14A - Seer, Inc. (0001726445) (Subject)
- PRThe Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.Proposal Provides Stockholders $2.40 per Share in Cash, a 42% Premium to the Unaffected Share Price, as Well as Potential Additional Value from the Sale of Seer's Assets via a Contingent Value Right Urges Seer's Independent Directors and Financial Advisor to Engage with the Radoff-JEC Group Regarding a Transaction and Avoid Further Value Destruction Under Current Leadership Team from Continued Operations Following Woeful Q1 2026 Results Reaffirms its Commitment to Holding the Board Accountable by Electing Three Highly Qualified, Independent Directors Who Are Best Suited to Rebuilding Value at Seer and Overseeing a Credible Strategic Review Process for the Benefit of All Stockholders B
- SECSEC Form 10-Q filed by Seer Inc.10-Q - Seer, Inc. (0001726445) (Filer)
- SECSeer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Seer, Inc. (0001726445) (Filer)
- PRSeer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 OutlookREDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo
- PRSeer Files Patent Infringement Lawsuit Against NanomicsSeer defends its pioneering Proteograph® Product Suite intellectual property (IP) REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit against Nanomics Biotechnology Co., Ltd. The asserted patents, U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, protect Seer's intellectual property in the field of nanoparticle protein enrichment. Brigham and Women's Hospital is joining this lawsuit as well. Seer has imagined and pioneered the first solution for standardized, robust, deep unbiased proteomics and has a
- INSIDERChief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)4 - Seer, Inc. (0001726445) (Issuer)
SEER FAQ
7 questionsWhat does Seer Inc. do?
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology...Where does SEER stock trade?
Seer Inc. (SEER) is listed on NASDAQ.What sector and industry is SEER in?
Seer Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Seer Inc. go public?
Seer Inc. (SEER) completed its IPO in 2020.What are analysts saying about SEER?
Seer Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $400.00 price target on 2026-05-04.What companies are similar to SEER?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare SEER side-by-side with any of them on Quantisnow.How can I track SEER on Quantisnow?
Quantisnow aggregates Seer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEER to receive live email and push alerts on every new disclosure.